ASX Lookahead

ASX Lookahead

Equities 6 minutes to read

Summary:  We look at potential drivers of Aussie stocks into year end and ahead to 2021. Can the ASX 200 lose the laggard status.


As we detailed in November, the vaccine trials have been higher than people expected in terms of efficacy. Giving equity markets broadly the luxury of glossing over near-term risks and focussing on the prospects of vaccine rollout and activity normalising next year. Hence, we continue to remain constructive on a medium-term outlook and focus on using any corrections to add to reopening trades (E.g. Cyclicals, small caps, commodities, emerging markets). For pro-cyclical stocks there is more room for normalisation and these sectors can look past immediate risks through to benefits a vaccine can provide.

Australia, despite having outperformed with respect to the COVID induced economic hit has lagged DM peers in terms of equity market performance. Australia’s relative success in containing the virus lends less relative upside from the vaccine. In addition, Asia also benefitting from the engine of China’s reflationary regime with broad scale infrastructure and construction stimulus, along with continued dollar weakness supporting flows into higher beta emerging markets. Added for Asia is a more favourable geopolitical tailwind with the incoming Biden administration expected to be less volatile in their approach to China vs. Australia still very much in the thick of an ongoing spat with China.

Although there are individual stocks and sectors that have been impacted by the AU/China tensions, the reopening and recovery in earnings and economic growth should take precedent at an index level. (Caveat – providing high value exports like iron ore do not come into the mix). In addition, for Australia the aggressive virus elimination strategy, with international border restrictions seemingly in place for a lengthy period at this stage, is an ongoing headwind for education and tourism – two high value services exports. 

However, the period ahead should bring plenty of opportunity for catch up, particularly taking into consideration the ongoing and overwhelming virus caseload, lockdowns and economic drags experienced by other regions, compared to a relatively virus free Australia. Of course, the hit to global activity and restrictive measures in place domestically still present a drag on Australia’s economy, but with a vaccine rollout ahead, earnings rebound in play and the prospect of regional travel bubbles in the pipeline Investors have something to look forward to which should see the index on a better footing into year end.

In addition, the resource heavy nature of the index could see the index shifting from underperformer to outperformer in the year ahead as various commodities rev-up into 2021 with a vaccine rollout, demand bounce back and fiscal spending tailwinds. Exposure to other investing thematics like the ESG/green transformation via battery metals, rare earths, copper and the like, also providing opportunity for investors.

As we transition toward an inflationary regime, with a synchronised global growth reacceleration coupled with unprecedented liquidity injections against the backdrop of extraordinary fiscal stimulus, we see a shift in market leadership toward cyclical sectors and geographies, real economy stocks, non-US markets and commodities. Therefore, the more cyclically orientated nature of the ASX 200 should support index performance throughout 2021 as the reflation rotation takes charge.

Financials, a heavyweight on the index will also be a driver in the year ahead. The rebounding growth picture along with higher yields supports the asset allocation from a macro standpoint. In addition for Australian banks a recovery in the housing market, buybacks, and better than expected outcome for bad debts will support the outlook for the sector.

For commodities, huge supply deficits with structural underinvestment, a vaccine-led recovery in global demand, green transformation tailwinds, and the engines of a weaker dollar plus higher inflation, coincide with a historic underweighting and a multiyear bear market to bring a broad commodity rally in 2021 – A trend that Australian stocks will benefit from.

Australian stocks with an abundance of commodity exposures present many selective buying opportunities for investors, as this regime shift is undertaken.

Energy - Aus Energy Sector still trades well below pre-COVID levels

Santos (STO:xasx)

Beach Energy (BPT:xasx)

Oil Search (OSH:xasx)

Copper – Green electrification tailwinds meets supply deficits

OZ Minerals (OZL:xasx)

Sandfire (SFR:xasx)

Lithium/Nickel – Green energy/EVs/Battery Metal

Orecobre (ORE:xasx)

Galaxy Resources (GXY:xasx)

Pilbara Minerals (PLS:xasx)

Western Areas (WSA:xasx)

Poseidon Nickel (POS:xasx)

Panoramic Resources (PAN:xasx)

Nickel Mines (NIC:xasx)

Iron Ore

BHP (BHP:xasx)

Rio Tinto (RIO:xasx)

Fortescue Metals (FMG:xasx)

Uranium – Supply squeeze due to low prices meets increasing demand with busiest global nuclear build program in decades

Paladin (PDN:xasx)

Lotus Resources (LOT:xasx)

Peninsula Energy (PEN:xasx)

NexGen Energy Ltd (NXE:xtse)

Bannerman (BMN:xasx)

Vimy Resources (VMY:xasx)

Rare Earths - ESG, National Security (non-Chinese supply), and EV exposure converge

US forming a Uranium + Rare Earths strategic reserve (MP Materials' Mountain Pass Mine will now become an even more valuable US strategic asset) - MP Materials Corp is one of the only ways to get exposure to American Rare Earths.

Post our initial buy recommendation in 2018, Australia-based Lynas remains in a pivotal position, as it is one of the only miner and processor/producer of rare earths worldwide outside of China.

Lynas (LYC:xasx)

MP Materials (MP:xnys)

Vaneck Rare Earth ETF (REMX:arcx)

Quarterly Outlook

01 /

  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992